Senior Editor, OncLive®
Courtney Marabella joined the MJH Life Sciences team in 2021 and is Senior Editor for OncLive®. Prior to joining the company she worked as the Audience Development Editor for the Asbury Park Press, part of the USA Today Network. Email: cmarabella@onclive.com
HEPZATO Demonstrates Promising Preliminary Activity in Metastatic Ocular Melanoma
March 31st 2021HEPZATO KIT has demonstrated statistically significant benefit compared to best alternative care in patients with liver-dominant metastatic ocular melanoma, according to preliminary results from the phase 3 FOCUS trial.
Read More
Novel NTD Inhibitor EPI-7386 Plus Enzalutamide Under Evaluation in mCRPC
March 31st 2021The first-in-class N-terminal domain androgen receptor inhibitor EPI-7386 is being examined in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer as part of a phase 1/2 trial.
Read More
Noninvasive cfDNA Blood Test for Advanced Adenoma and CRC Under Exploration
March 31st 2021A prospective, multicenter, observational USOPTIVAL study has been initiated in the United States to examine an investigational cell-free DNA blood test to detect advanced adenoma and colorectal cancer.
Read More
COVID-19 and Cancer Care: Lessons Learned 1 Year Later
March 31st 2021From delayed diagnoses, to the emergence of telemedicine, to managing the increased emotional burden experienced by patients and healthcare professionals alike, the community has been forced to approach cancer care in ways they never had before in light of the COVID-19 pandemic.
Read More
Liso-Cel Approved in Japan for Relapsed/Refractory Large B-Cell Lymphoma
March 29th 2021Japan’s Ministry of Health, Labour and Welfare has approved lisocabtagene maraleucel, a CAR T-cell therapy designed to target CD19, for the treatment of patients with relapsed or refractory large B-cell lymphoma, as well as relapsed/refractory follicular lymphoma.
Read More
Chemotherapy Plus Immunotherapy Shows No Benefit Following Osimertinib in EGFR+ NSCLC
March 26th 2021Treatment with chemotherapy plus immunotherapy did not demonstrate significant clinical benefit over chemotherapy alone in patients with EGFR-mutated non–small cell lung cancer after progression on osimertinib.
Read More
Tipifarnib Showcases Encouraging Efficacy in Relapsed or Metastatic HRAS-Mutant HNSCC
March 26th 2021Tipifarnib showed promising clinical activity in patients with recurrent and/or metastatic, HRAS-mutant head and neck squamous cell carcinoma whose disease had progressed after prior therapy.
Read More
The fatty acid synthase inhibition caused by AZ12756122 could represent a promising therapeutic alternative to overcome resistance to EGFR TKIs because of the synergistic interaction that it has with osimertinib and its ability to reduce cancer stem cell properties in EGFR-mutant non–small cell lung cancer cell models.
Read More
Northfelt Navigates Advances Made to Improve iDFS, Reduce Relapse Risk in ER+ Breast Cancer
March 24th 2021Donald W. Northfelt, MD, MS, FACP, discusses the progress made with CDK4/6 inhibitors in the treatment of patients with ER-expressing breast cancer and pivotal trials that have moved the needle forward.
Read More
Messersmith Makes Sense of the Novel Approaches on the Rise in GI Malignancies
March 23rd 2021The pipeline of new agents in gastrointestinal cancers is robust, with the emergence of several antibody-drug conjugates, KRAS G12C inhibitors, and novel TKI/immune checkpoint inhibitor combinations.
Read More
AVB-500/Paclitaxel Demonstrates Clinical Benefit in Platinum-Resistant Ovarian Cancer
March 23rd 2021The GAS6/AXL inhibitor AVB-500, when combined with paclitaxel, elicited clinical benefit with favorable tolerability in patients with platinum-resistant ovarian cancer, according to data from a phase 1b study.
Read More
Eribulin Demonstrates Limited Activity in Advanced or Recurrent Cervical Cancer
March 20th 2021Eribulin induced limited activity with a favorable toxicity profile in patients with recurrent or advanced cervical cancer, and prior exposure to paclitaxel was associated with decreased response to the agent.
Read More
Santos Spotlights Success With Checkpoint Inhibition in Frontline Metastatic NSCLC
March 18th 2021Edgardo Santos, MD, FACP, discusses advances made with immunotherapy regimens in the first-line treatment of patients with metastatic non–small cell lung cancer and areas of active investigation.
Read More
Promises and Pitfalls of MRD as a Potential Surrogate End Point in AML
March 18th 2021Jerald Radich, MD, highlights the role minimal residual disease in acute myeloid leukemia, how different technological advanced have increased the application of MRD-based strategies, and ongoing efforts that are being made to address remaining questions.
Read More
Cilta-Cel Demonstrates Durable Responses in Relapsed/Refractory Multiple Myeloma
March 17th 2021Ciltacabtagene autoleucel has a manageable safety profile at its recommended phase 2 dose, and yielded early, deep, and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.
Read More
Risk-Adapted CAR T Dosing Maintains Efficacy, Improves Safety in Pediatric Relapsed/Refractory ALL
March 15th 2021A risk-adapted CD19 CAR T-cell therapy dosing approach allowed pediatric patients with relapsed/refractory acute lymphocytic leukemia to maintain a high rate of remission, while reducing the risk of severe toxicities among those with a high initial disease burden
Read More
Comprehensive Genomic Testing Alters the Rapidly Evolving Cholangiocarcinoma Treatment Landscape
March 12th 2021Daniel Lin, MD, MS, discusses pivotal trials examining important targeted agents for patients with cholangiocarcinoma and the importance of comprehensive genomic testing to guide treatment decisions.
Read More
Addressing Treatment Disparities Among Younger Women with Breast Cancer
March 6th 2021Even in 2021, disparities in outcomes of younger women with breast cancer vs their older counterparts remain; addressing behavioral issues and psychological concerns in this population could vastly improve their quality of life, treatment adherence, and ultimately, survival.
Read More
Ilixadencel/Sunitinib Combo Showcases Promising Survival Benefit in mRCC
February 24th 2021February 24, 2021—The off-the-shelf immune primer ilixadencel in combination with sunitinib showcased an encouraging, clinically meaningful survival benefit when used in the first-line treatment of newly diagnosed patients with metastatic renal cell carcinoma.
Read More